[go: up one dir, main page]

AR066511A2 - Composicion farmaceutica que comprende una molecula ctla4 soluble y un segundo agente y uso de la ctla4 soluble para preparar la composicion farmaceutica - Google Patents

Composicion farmaceutica que comprende una molecula ctla4 soluble y un segundo agente y uso de la ctla4 soluble para preparar la composicion farmaceutica

Info

Publication number
AR066511A2
AR066511A2 ARP080101975A ARP080101975A AR066511A2 AR 066511 A2 AR066511 A2 AR 066511A2 AR P080101975 A ARP080101975 A AR P080101975A AR P080101975 A ARP080101975 A AR P080101975A AR 066511 A2 AR066511 A2 AR 066511A2
Authority
AR
Argentina
Prior art keywords
agent
pharmaceutical composition
ctla4
soluble
molecula
Prior art date
Application number
ARP080101975A
Other languages
English (en)
Inventor
Robert Cohen
Suzette Carr
Robert J Peach
Jean-Claude Becker
David Hagerty
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066511(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR066511A2 publication Critical patent/AR066511A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

El uso de un primer agente y un segundo agente, en donde a) el primer agente es una molécula mutante soluble CTLA4, y b) el segundo agente está seleccionado del grupo que consiste en corticosteroides, fármacos antiinflamatorios no esteroides, ciclosporina prednisona, azatioprina, metotrexato, bloqueantes o antagonistas de TNFalfa, infliximab, cualquier agente biologico dirigido a citoquina inflamatoria, hidroxicloroquina, sulfasalazopriína, sales áuricas, etanercept y anakinra para la preparacion de una composicion farmacéutica para bloquear interacciones de B7 con CTLA4 y/o CD28.
ARP080101975A 2000-07-03 2008-05-09 Composicion farmaceutica que comprende una molecula ctla4 soluble y un segundo agente y uso de la ctla4 soluble para preparar la composicion farmaceutica AR066511A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21591300P 2000-07-03 2000-07-03

Publications (1)

Publication Number Publication Date
AR066511A2 true AR066511A2 (es) 2009-08-26

Family

ID=22804919

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010103156A AR035037A1 (es) 2000-07-03 2001-07-02 Metodos para tratar enfermedades reumaticas al usar una molecula ctla4 soluble
ARP080101975A AR066511A2 (es) 2000-07-03 2008-05-09 Composicion farmaceutica que comprende una molecula ctla4 soluble y un segundo agente y uso de la ctla4 soluble para preparar la composicion farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010103156A AR035037A1 (es) 2000-07-03 2001-07-02 Metodos para tratar enfermedades reumaticas al usar una molecula ctla4 soluble

Country Status (38)

Country Link
US (1) US7455835B2 (es)
EP (4) EP1372696B1 (es)
JP (1) JP2004517806A (es)
KR (3) KR100864120B1 (es)
CN (1) CN1318086C (es)
AR (2) AR035037A1 (es)
AT (1) ATE401909T1 (es)
AU (2) AU7317401A (es)
BG (2) BG66024B1 (es)
BR (1) BR0112104A (es)
CA (2) CA2413190C (es)
CY (3) CY1109786T1 (es)
CZ (1) CZ303959B6 (es)
DE (1) DE60135029D1 (es)
DK (2) DK1935427T3 (es)
EE (1) EE05378B1 (es)
ES (2) ES2310557T3 (es)
HR (1) HRP20030071B1 (es)
HU (3) HU226847B1 (es)
IL (2) IL153593A0 (es)
IS (1) IS2834B (es)
LT (2) LT1935427T (es)
LV (1) LV12993B (es)
MX (1) MXPA02012603A (es)
MY (1) MY137552A (es)
NO (3) NO20026264L (es)
PE (1) PE20020772A1 (es)
PL (2) PL212205B1 (es)
PT (2) PT1935427T (es)
RS (1) RS50811B (es)
RU (1) RU2287340C2 (es)
SI (3) SI1935427T1 (es)
SK (1) SK287940B6 (es)
TR (1) TR201807700T4 (es)
TW (2) TWI322153B (es)
UY (1) UY26815A1 (es)
WO (1) WO2002002638A2 (es)
ZA (1) ZA200210058B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02011534A (es) * 2000-05-26 2004-08-12 Bristol Myers Squibb Co Moleculas mutantes ctla4 solubles y uso de las mismas.
CA2411962A1 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
EP1670499A4 (en) * 2003-08-04 2009-07-22 Bristol Myers Squibb Co METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TWI423986B (zh) * 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2222697B1 (en) * 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) * 2007-11-01 2014-08-28 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2014250683B2 (en) * 2007-11-01 2015-11-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
ES2615861T3 (es) * 2008-10-30 2017-06-08 Yeda Research And Development Company Ltd. Células T de memoria central anti-terceros, métodos de producción de las mismas y uso de las mismas en trasplante y tratamiento de enfermedades
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
PT3053932T (pt) * 2010-02-19 2020-10-21 Xencor Inc Novas imunoadesinas ctla4-ig
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
CN103270050A (zh) 2010-09-08 2013-08-28 耶达研究及发展有限公司 用于稳定和长期移植的免疫抑制药物组合
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
WO2013010537A1 (en) * 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
MX351226B (es) 2011-09-08 2017-10-05 Yeda Res & Dev Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades.
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
MX377570B (es) 2012-06-27 2025-03-10 Orban Biotech Llc Proteínas de fusión ctla4 para el tratamiento de la diabetes.
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
EA201692126A1 (ru) * 2014-04-25 2017-03-31 Бристол-Маерс Сквибб Компани Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра)
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
WO2017009852A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
EP3571295A1 (en) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019175380A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210023209A1 (en) 2018-03-16 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
ES3011707T3 (en) 2019-01-15 2025-04-08 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP2025016812A (ja) * 2021-12-16 2025-02-05 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644792A (en) * 1899-09-14 1900-03-06 Stanhope Boal Heater.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
US5958403A (en) 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
DE69333580D1 (de) 1992-04-07 2004-09-09 Univ Michigan Immunregulation über die cd28-route
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
DE69434342T2 (de) 1993-06-04 2006-03-16 The United States Of America Represented By The Secretary Of The Navy Verfahren zur selektiven Stimulierung der T-Zellproliferation.
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
EP0806204A4 (en) * 1993-12-01 2001-06-27 Sankyo Co Inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0784482A2 (en) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5634055A (en) * 1994-09-27 1997-05-27 Bidplus, Inc. Method for selecting assignments
AU4158396A (en) 1994-11-10 1996-06-06 Dana-Farber Cancer Institute Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK0892643T4 (da) 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
IL133070A0 (en) 1997-06-11 2001-03-19 Us Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
AU2999199A (en) * 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
WO1999062525A1 (en) * 1998-06-05 1999-12-09 Supergen, Inc. Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
JP2000086519A (ja) * 1998-09-17 2000-03-28 Mitsui Chemicals Inc 抗リウマチ薬効果増強剤
IL126681A0 (en) 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001264936A1 (en) 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the ctla4 gene
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02011534A (es) 2000-05-26 2004-08-12 Bristol Myers Squibb Co Moleculas mutantes ctla4 solubles y uso de las mismas.
CA2411962A1 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PT1397153E (pt) * 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis

Also Published As

Publication number Publication date
BG66454B1 (bg) 2014-10-31
DK1935427T3 (en) 2018-06-06
WO2002002638A2 (en) 2002-01-10
IL153593A (en) 2009-09-01
TR201807700T4 (tr) 2018-06-21
LV12993B (en) 2003-10-20
HUS1000008I1 (hu) 2019-06-28
EP3384924A1 (en) 2018-10-10
AR035037A1 (es) 2004-04-14
HU227669B1 (en) 2011-11-28
EP1372696A2 (en) 2004-01-02
HUP0301727A2 (hu) 2003-09-29
BR0112104A (pt) 2004-07-20
AU2001273174B2 (en) 2006-05-18
SK287940B6 (sk) 2012-05-03
KR20030017606A (ko) 2003-03-03
US7455835B2 (en) 2008-11-25
LT5063B (lt) 2003-11-25
HUP0301727A3 (en) 2008-08-28
ES2667203T3 (es) 2018-05-10
TW200902546A (en) 2009-01-16
NO20026264D0 (no) 2002-12-27
CY1120577T1 (el) 2019-07-10
IS2834B (is) 2013-05-15
NO20100579L (no) 2003-02-19
CZ303959B6 (cs) 2013-07-17
KR100864120B1 (ko) 2008-10-16
BG107362A (bg) 2003-09-30
IL153593A0 (en) 2003-07-06
PL365942A1 (en) 2005-01-24
CY2008017I2 (el) 2016-08-31
NO20100580L (no) 2003-02-19
PT1935427T (pt) 2018-05-16
UY26815A1 (es) 2002-01-31
NO20026264L (no) 2003-02-19
HU226847B1 (en) 2009-12-28
TWI311564B (en) 2009-07-01
CA2413190C (en) 2009-04-07
PT1372696E (pt) 2008-10-24
EE200300004A (et) 2004-10-15
KR20080075564A (ko) 2008-08-18
CA2630062A1 (en) 2002-01-10
PL212205B1 (pl) 2012-08-31
IS6667A (is) 2003-01-02
SI1935427T1 (en) 2018-05-31
LT2003002A (en) 2003-07-25
BG110611A (bg) 2010-05-31
ATE401909T1 (de) 2008-08-15
ZA200210058B (en) 2005-02-23
EE05378B1 (et) 2011-02-15
EP1935427A3 (en) 2011-05-25
HRP20030071A2 (en) 2005-02-28
EP1372696B1 (en) 2008-07-23
SK17742002A3 (sk) 2004-11-03
SI21078A (sl) 2003-06-30
BG66024B1 (bg) 2010-11-30
CY2008017I1 (el) 2009-11-04
EP1935427B1 (en) 2018-03-07
LT1935427T (lt) 2018-05-10
HRP20030071B1 (hr) 2014-01-03
YU101102A (sh) 2006-01-16
CA2630062C (en) 2014-10-14
CA2413190A1 (en) 2002-01-10
AU7317401A (en) 2002-01-14
EP2281568A3 (en) 2013-04-24
AU2001273174C1 (en) 2002-01-14
PL207534B1 (pl) 2010-12-31
MXPA02012603A (es) 2003-05-14
DE60135029D1 (de) 2008-09-04
CZ20024261A3 (cs) 2004-08-18
RS50811B (sr) 2010-08-31
SI1372696T1 (sl) 2008-12-31
DK1372696T3 (da) 2008-11-03
WO2002002638A3 (en) 2003-10-30
MY137552A (en) 2009-02-27
EP1935427A2 (en) 2008-06-25
CY1109786T1 (el) 2011-04-06
EP2281568A2 (en) 2011-02-09
JP2004517806A (ja) 2004-06-17
CN1477968A (zh) 2004-02-25
US20030083246A1 (en) 2003-05-01
KR20080025216A (ko) 2008-03-19
TWI322153B (en) 2010-03-21
ES2310557T3 (es) 2009-01-16
KR100895552B1 (ko) 2009-04-29
RU2287340C2 (ru) 2006-11-20
PE20020772A1 (es) 2002-09-06
CN1318086C (zh) 2007-05-30
HK1058486A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AR066511A2 (es) Composicion farmaceutica que comprende una molecula ctla4 soluble y un segundo agente y uso de la ctla4 soluble para preparar la composicion farmaceutica
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
EP1790340A3 (en) Combination chemotherapy
AR012247A1 (es) Composiciones farmaceuticas y su uso para la preparacion de medicamentos destinados a prevenir y tratar las enfermedades tromboembolicas arteriales
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
AR011611A1 (es) Composiciones en gel postespumante
DE60005493D1 (de) Pyrimido[6,1-a]isochinolinonderivate
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
AR030245A1 (es) Composiciones de gel que contienen metronidazol
GT199800042A (es) Nuevos derivados del acido hexanoico.
CR9950A (es) Composiciones farmaceuticas solidas que contienen pregabalina
AR042536A1 (es) Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
BR9914718A (pt) Formulações farmacêuticas de libertação controlada compreendendo um inibidor cgmp pde-5
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
AR003626A1 (es) Composicion tixotropica de limpieza de superficies duras y uso de dicha composicion
DK0722316T3 (da) Nyt emulsionspræparat
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu

Legal Events

Date Code Title Description
FB Suspension of granting procedure